Testing PARP inhibitors with peptide radiation for NET
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a NET that has spread or is locally advanced
- Your tumor is “well-differentiated” (grade 1–3) based on biopsy results
- Your disease has progressed after PRRT using 177Lu-DOTATATE, and you may still be able to have two more PRRT cycles
- Your scans show the right docking sites (“somatostatin receptors”) on the tumors using a 68Ga-DOTATATE (or related) PET scan
- You have measurable tumors on CT or MRI, and you are able to do study activities (Karnofsky score over 60)
- Your blood and organ tests are safe enough for treatment (lower limits for blood counts, kidney, and liver function apply)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial uses a special PET scan with a radioactive tracer called [18F]-Olaparib to see how head and neck cancers respond to DNA damage during chemoradiotherapy. It may help doctors understand which patients benefit most from treatment.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.